Nymox Pharmaceutical Corp 6-K, filed May 22, 2025
Nymox Pharmaceutical Corp (NYMXF)
About this 6-K
Nymox Pharmaceutical Corp filed this 6-K on May 22, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May, 2025
Commission File Number: 001-12033
| Nymox Pharmaceutical Corporation |
| (Translation of registrant’s name into English) |
Bay & Deveaux Streets, Nassau, The Bahamas
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40‑F.
Form 20-F ☒ Form 40-F ☐
Nymox Pharmaceutical Corporation (the “Company”) has been made aware that 2 individuals formerly affiliated with the Company have filed complaints against it, alleging various claims associated with their termination for cause. These individuals are 2 of the same plaintiffs awaiting their court ordered requirement to pay the Company substantial legal fees and damages after they lost on their request for an injunction against the Company. The Company believes the claims are without merit and intends to defend against them.
| 2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 22, 2025
| NYMOX PHARMACEUTICAL CORPORATION | |||
|
|
|
| |
|
| By: | /s/ Paul Averback |
|
|
| Name: | Paul Averback | |
|
| Title: | President and Chief Executive Officer | |
| 3 |